HC Wainwright Reduces Earnings Estimates for Altimmune

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at HC Wainwright reduced their FY2024 earnings estimates for Altimmune in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.28) per share for the year, down from their previous forecast of ($1.25). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Altimmune’s Q1 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($1.45) EPS and FY2028 earnings at ($0.15) EPS.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter. During the same period last year, the business posted ($0.39) EPS.

A number of other research analysts have also weighed in on the company. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a report on Friday, August 9th. B. Riley reiterated a “buy” rating and issued a $20.00 target price on shares of Altimmune in a report on Monday, August 12th. Finally, UBS Group initiated coverage on shares of Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Price Performance

NASDAQ:ALT opened at $7.61 on Monday. Altimmune has a one year low of $2.34 and a one year high of $14.84. The company has a market cap of $541.22 million, a PE ratio of -4.91 and a beta of 0.09. The firm has a 50-day moving average of $7.02 and a 200-day moving average of $6.91.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently made changes to their positions in ALT. Geode Capital Management LLC raised its holdings in shares of Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after acquiring an additional 74,194 shares in the last quarter. Bellevue Group AG lifted its position in Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after purchasing an additional 263,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Altimmune by 142.9% during the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares during the period. Knoll Capital Management LLC increased its stake in shares of Altimmune by 183.6% in the first quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after buying an additional 367,219 shares during the period. Finally, Farallon Capital Management LLC boosted its position in Altimmune by 1,282.4% during the 1st quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after buying an additional 436,000 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.